Archives
-
Mechanistic qPCR for Translational CRC Research
2026-09-28
A mechanistic and strategic guide to using SYBR Green qPCR for validating apoptosis and chemosensitization signals in colorectal cancer research, with practical guidance for selecting and deploying HotStart™ 2X Green qPCR Master Mix.
-
FITC-Concanavalin A (ConA) Conjugate Guide
2026-09-28
FITC-Concanavalin A (ConA) Conjugate provides a fluorescent readout for accessible α-D-glucose and α-D-mannose residues on cell surfaces and in tissue samples. Use it as a carbohydrate-binding probe in immunofluorescence or flow cytometry workflows, not as a general protein stain or a detector of non-carbohydrate targets.
-
WY-14643: A PPARα Lens on Lipid Homeostasis
2026-09-27
WY-14643 (Pirinixic Acid) offers researchers a pharmacological way to probe PPARα-linked lipid regulation, inflammation, and metabolic phenotypes. A recent PFHxS study shows why this pathway matters in environmental biology—and why careful controls are essential when translating receptor activation across models.
-
FITC-Concanavalin A (ConA) Conjugate Guide
2026-09-26
FITC-Concanavalin A is a fluorescent lectin conjugate for visualizing accessible α-D-glucose- and α-D-mannose-containing structures on cells and tissue samples. Use it for carbohydrate-focused immunofluorescence staining or flow cytometry—not to detect non-carbohydrate targets—and optimize staining conditions for each sample.
-
Licoricidin in HCC: Growth, Metastasis, and PI3K/AKT
2026-09-25
A preclinical study reports that licoricidin suppresses hepatocellular carcinoma cell growth and metastatic behavior, with results associated with cell-cycle arrest, apoptosis, altered EMT markers, and reduced PI3K/AKT signaling. The findings connect in vitro assays with xenograft and metastasis models, but do not yet establish a direct molecular target or clinical efficacy.
-
Nilotinib and UV Stress: Separating Signaling
2026-09-25
Nilotinib (AMN-107) offers a defined way to interrogate BCR-ABL, KIT, and related kinase signaling in cancer models. This article connects that target-specific approach to new findings on UV-triggered ribotoxic stress—and explains how to distinguish pathway engagement from cell death without implying an unproven drug effect.
-
Ruxolitinib in JAK-STAT Bench Workflows
2026-09-24
Use Ruxolitinib (INCB018424) to probe JAK1/2-dependent signaling alongside, rather than in place of, studies of upstream innate immune activation. This workflow pairs pathway-specific phospho-readouts with cytokine and viability measurements, helping separate direct JAK-STAT effects from broader changes in inflammatory responses.
-
Adipose Netrin-1 in Metabolic Regulation
2026-09-24
This study examines how adipose Netrin-1 relates to adipose tissue biology and systemic metabolic regulation, combining mouse models, cell experiments, and analysis of human adipose tissue datasets.
-
Apicidin: From HDAC Inhibition to Assay Causality
2026-09-23
Apicidin is a potent histone deacetylase inhibitor, but interpreting its effects requires separating enzyme engagement from downstream cell stress. This article uses recent oocyte findings to explain how to design more discriminating assays and avoid over-attributing complex phenotypes to one HDAC target.
-
Hexamethonium Bromide in Autonomic Translation
2026-09-23
A translational framework for using Hexamethonium Bromide to dissect autonomic ganglia function, nicotinic acetylcholine receptor signaling, and sex-dependent cardiovascular regulation in conscious hypertension models.
-
WNK3–PER1 Control of Circadian Rhythms in Rats
2026-09-22
The reference study links the serine/threonine kinase WNK3 to PER1 regulation in the rat suprachiasmatic nucleus, connecting kinase activity with sleep-related circadian phenotypes. Its results support a model in which WNK3 phosphorylates PER1, promotes PER1 degradation, and contributes to molecular clock oscillation, while also illustrating how phosphorylation measurements can strengthen circadian biology studies.
-
Decitabine: DNA Methylation and Cancer Research
2026-09-22
Decitabine, also called 5-Aza-2'-deoxycytidine, is a DNA methyltransferase inhibitor that can reduce maintenance DNA methylation after incorporation into DNA. Its strongest established clinical role is in myelodysplastic syndromes, while gastric and other solid-tumor applications remain model- and protocol-dependent research areas.
-
HDAC Inhibition Reverses EBV-Driven NPC Plasticity
2026-09-21
This study defines a mechanistic route by which EBV LMP1 promotes dedifferentiation and stem-like plasticity in nasopharyngeal carcinoma through STAT5A-dependent recruitment of HDAC1/2 to the CEBPA locus. Its xenograft evidence supports HDAC inhibition as a differentiation-oriented strategy for reversing this phenotype, while also highlighting the need for biomarker-guided validation in clinically representative models.
-
Lenalidomide (CC-5013) in Myeloma Research
2026-09-21
Lenalidomide (CC-5013) supports integrated myeloma workflows that connect tumor-cell viability with immune signaling, angiogenesis, and epigenetic combination studies. This practical guide shows how to prepare, dose, monitor, and troubleshoot experiments using evidence from a recent DOT1L study.
-
Exo1 for Mechanistic Exocytosis Assays
2026-09-20
Exo1, or methyl 2-(4-fluorobenzamido)benzoate, is a mechanistically distinct tool for acute membrane trafficking inhibition. This guide connects Golgi–ER perturbation to extracellular-vesicle assay design while separating validated evidence from translational hypotheses.